Alain Beck | Senior Director
Centre d'Immunologie Pierre Fabre

Dr Alain Beck is Senior Director, Biologics CMC and Developability (Institut de Recherche Pierre Fabre, France), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics R&D programs including dalotuzumab/ IGF1R (Ph2/3, Merck), telisotuzumab, telisotuzumab vedotin (Emrelis, FDA approved 2025) and adizutecan/ cMet (Ph3, AbbVie)), h515H7/ CXCR4 mAb, lonigutamab (Ph2, Alumis/ Acelyrin) and lonigutamab ugodotin ADC/ IGF1R, W0180 Vista IO mAb (Ph1, PF), VERT-002/ cMet (Vertical Bio) and efsudenermin alpha fusion protein (Ph2, Fc:EDA1, ER004, Esperare Foundation). He is author/ co-author of +270 publications (h-index: 74; +20,000 citations). He has contributed to +300 scientific meetings worldwide (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chairman, invited keynote speaker, panellist, moderator, advisor, and/or organizer (ADCs/ BsADCs, IO mAbs, Biobetters, Biosimilars, pAbs, Bs/ MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013), was winner of 6th WADC (2019), 10th AIS (2022) and Medicine Maker Power List 2024 awards. He is member of the MAB Working Party (EDQM/ PhEur) and involved in scientific and regulatory workshops with ANSM, EU, EMA, FDA, NIST USP and WHO.